Prospective Clinical Trial of Three Apical Sealing Materials

Phase 4CompletedNCT04198298

University of the Pacific59 enrolled

Overview

This prospective comparative randomized clinical trial compares healing and bony regeneration in patients who received 1 of 3 different retrograde filling materials following microsurgical apicoectomies for the treatment of periapical lesions of endodontic origin.

A prospective comparative randomized clinical trial was designed to evaluate the healing and bony regeneration in patients who received 1 of 3 different retrograde filling materials (EndoSequence®, ProRoot® MTA, or Biodentine®) following microsurgical apicoectomies for the treatment of periapical lesions of endodontic origin.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Periapical Abscess

Interventions

EndoSequenceDRUG

The EndoSequence® retrograde sealing material was used to provide a biologic seal at the apex.

ProRoot MTADRUG

The ProRoot® MTA retrograde sealing material was used to provide a biologic seal at the apex.

BiodentineDRUG

The Biodentine® retrograde sealing material was used to provide a biologic seal at the apex.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, American Society of Anesthesiologists (ASA) classification I and II * Any tooth with a single chronic periapical lesion requiring apical microsurgery * Informed consent signed prior to surgery Exclusion Criteria: * Background of drug/alcohol abuse * Adjacent periapical lesion * Periodontal disease

Outcomes

Primary Outcomes

Rate of remineralization

The pace at which new bone is redeposited

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.